A generation of CAR T cells targeting EGFR were engineered by Li H. et al. (2018), which, upon testing, showed antitumor as well as expansion capabilities in vitro and prolonged the survival of immunodeficient mice bearing human lung cancer cells, by reducing the cancer tumor burden with no associated toxicity. The gene discussed is EGFR; the disease is neoplasm.